8-K: Crown Laboratories Completes Acquisition of Revance Therapeutics for $3.65 Per Share

Crown Laboratories finalizes its acquisition of Revance Therapeutics, reinforcing its position in the aesthetics and skincare market.

Summary

• Crown Laboratories has completed its acquisition of Revance Therapeutics.
• The acquisition was finalized on February 6, 2025.
• Crown acquired all outstanding shares of Revance for $3.65 per share in cash.
• A total of 86,197,893 shares were validly tendered, representing approximately 82% of the outstanding shares.
• Revance's common stock will be delisted from the NASDAQ Global Select Market.
• The merger was completed following a tender offer that expired on February 4, 2025.
• Revance has become a wholly-owned subsidiary of Crown Laboratories.
• Holders of Revance's 2027 Convertible Senior Notes will now have the right to convert their notes into cash, based on a formula related to the acquisition price.
• The directors of Revance resigned, and Jeffery A Bedard became the sole director of the company.
• Revance's certificate of incorporation and bylaws were amended and restated.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The acquisition is completed, providing liquidity to shareholders and convertible noteholders. Crown Laboratories expands its market position. However, Revance is delisted, and there are integration risks.

Positives

• Crown Laboratories strengthens its position in the aesthetics and skincare industry through this acquisition.
• Revance stockholders received $3.65 per share in cash.
• The acquisition provides liquidity for Revance's convertible noteholders, allowing them to convert their notes into cash.

Negatives

• Revance's common stock will be delisted from the NASDAQ Global Select Market.
• The directors of Revance resigned as directors of the Company.
• Following completion of the Merger, all of the incumbent officers of the Company, as of immediately prior to the effectiveness of the Merger, were removed as officers of the Company.

Risks

• There are potential difficulties or unanticipated expenses in integrating the operations of Revance and Crown.
• Anticipated synergies and benefits of the transaction may not be realized as expected.
• The merger could affect Revance's and Crown's business relationships.

Future Outlook

Crown Laboratories aims to strengthen its position as a leading aesthetics and skincare company through the acquisition of Revance Therapeutics.

Management Comments

• Crown Laboratories is committed to developing and providing a diverse portfolio of aesthetic, premium and therapeutic skincare products that improve the quality of life for its consumers throughout their skincare journey.
• Crown's unyielding pursuit of delivering therapeutic excellence and enhanced patient outcomes is why it has become a leader in Dermatology and Aesthetics.

Industry Context

The acquisition reflects a trend of consolidation in the aesthetics and skincare industry, with larger companies acquiring innovative firms to expand their product portfolios and market reach.

Comparison to Industry Standards

• The acquisition of Revance by Crown Laboratories is similar to other acquisitions in the pharmaceutical and skincare industries, such as Allergan's acquisition by AbbVie, where larger companies acquire smaller, innovative firms to expand their product offerings.
• The $3.65 per share acquisition price is within the range of typical premiums paid in similar acquisitions, though the specific premium depends on Revance's financial performance and market conditions at the time of the offer.
• Comparable companies in the aesthetics market include Galderma and Merz Pharma, which also focus on developing and marketing innovative skincare and aesthetic products.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders of Revance received cash for their shares.
• Employees of Revance may experience changes as the company integrates with Crown Laboratories.
• Customers of Revance will likely see continued availability of products under the new ownership.
• Convertible noteholders will receive cash upon conversion of their notes.

Next Steps

• Revance's common stock will be delisted from the NASDAQ Global Select Market.
• Revance intends to file a certification and notice of termination of registration on Form 15 with the SEC requesting the termination of registration of the Shares under Section 12(g) of the Exchange Act and the suspension of reporting obligations under Sections 13 and 15(d) of the Exchange Act with respect to the Shares.

Key Dates

Keywords

acquisition, merger, Revance Therapeutics, Crown Laboratories, tender offer, delisting, convertible notes, aesthetics, skincare